decisionhealth Newsletters, Coder Pink Sheets - 2003 Issue 12 (December)
Drugs
Subscribe or sign in to view the full article.
Article Overview
This article explains a compliance issue for medical practices considering drug acquisition from Canada. It focuses on FDA jurisdiction, the distinction between FDA and Medicare/CMS oversight, and the legal concerns that can arise when drugs purchased outside the U.S. are used or billed in the U.S. The article is relevant to practice administrators, billing staff, and clinicians who handle drug purchasing and reimbursement decisions.
Why This Topic Matters
Practices may be reimbursed for drugs without realizing there are separate federal regulatory risks tied to how the drugs were obtained. The article helps readers recognize that billing payment does not necessarily eliminate FDA or False Claims Act concerns.
What You Will Learn
- Why Canadian drug purchases can create compliance concerns for U.S. medical practices.
- How FDA oversight differs from Medicare/CMS reimbursement considerations.
- Why drug sourcing and re-importation issues matter for billing and regulatory risk.
- What general enforcement concerns may apply to imported drugs.
Who Should Read This
- Physician practices
- Practice administrators
- Billing and coding staff
- Compliance professionals
- Healthcare attorneys
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com